In 2018, Domain Therapeutics and Boehringer Ingelheim entered into a multi-target collaboration and licensing agreement to address orphan GPCR for neuropsychiatric disorders and potential other indications (see press release).
Multi-target collaboration for CNS
Initiated in 2018, the multi-target drug discovery collaboration focuses on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area. The collaboration combines our expertise in the discovery of candidate targeting orphan GPCR, with Boehringer Ingelheim’s expertise in the discovery and regulatory development of therapeutics on multiple indications.
The achievement of two discovery milestones was announced in September 2019.